TAK-003

A new vaccine for dengue received prequalification from the World Health Organization (WHO) on 10 May 2024. TAK-003 is the second dengue vaccine to be prequalified by WHO. Developed by Takeda, it is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue. 

WHO recommends the use of TAK-003 in children aged 6–16 years in settings with high dengue burden and transmission intensity. The vaccine should be administered in a 2-dose schedule with a 3-month interval between doses. 

WHO News

<<< About Dengue

Comments

Popular posts from this blog

Russian parliament passed a bill to revoke its ratification of the Comprehensive Test Ban Treaty

Interstellar space and Interstellar Probes ( Voyager and New Horizons Missions )

ISRO developing semi-cryogenic engine working on LOX Kerosene propellant